New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Psyence Biomedical Ltd.

PBM

Healthcare Biotechnology

2.97 0.11 +3.85%

After hours trading: 3.01, up 1.35%, last trade Fri 4:09pm Eastern.

Market cap
$10.9M
P/E
0.1×
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
1.2×
Payout ratio
—

Where the cash went Fiscal 2026, year to Mar 31, 2026

Free cash flow was −$8.1M: capital expenditures were more than operating cash flow. Cash rose by $1.3M. Lines the picture does not name came to +$14.0M. What is a cash flow statement?

Free cash flow
−$8.1M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
+$1.3M over the period
Where the cash went, in millions of dollars
Operating cash flow−8.1
Free cash flow−8.1
Into investments, net−4.5
Other+14.0
Change in cash1.3
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, three years
FY24FY25FY26
Operating cash flow−$2.9M−$3.7M−$8.1M
Capex$0$0$0
Free cash flow−$3M−$3.7M−$8.1M

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Dec '17 Jan '21 Jan '22 Dec '23 Mar '24 Mar '25 Mar '26
Net Income
0.00 8.23 8.01 0.00 (51.16) 1.01 (6.94)
Operating Cash Flow
— (0.84) (0.52) — (2.95) (3.73) (8.14)
Investing cash flow
— (255.00) — — (0.01) (0.02) (4.51)
Financing cash flow
— 256.49 — — 2.35 9.15 13.96
Ending Cash
— — — — 0.73 6.14 7.44

Show all line items

In millions of $ except per-share values · columns are period end dates